1. Home
  2. CURI vs MOLN Comparison

CURI vs MOLN Comparison

Compare CURI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CuriosityStream Inc.

CURI

CuriosityStream Inc.

HOLD

Current Price

$3.34

Market Cap

193.6M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.22

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURI
MOLN
Founded
N/A
2004
Country
United States
Switzerland
Employees
45
N/A
Industry
Movies/Entertainment
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
193.6M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CURI
MOLN
Price
$3.34
$4.22
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$5.83
$8.38
AVG Volume (30 Days)
376.4K
2.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.52
N/A
Revenue Next Year
$16.90
$285.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$3.36
52 Week High
$7.15
$5.36

Technical Indicators

Market Signals
Indicator
CURI
MOLN
Relative Strength Index (RSI) 46.16 32.57
Support Level $3.07 $4.02
Resistance Level $4.96 $4.61
Average True Range (ATR) 0.19 0.22
MACD 0.01 -0.09
Stochastic Oscillator 40.96 0.00

Price Performance

Historical Comparison
CURI
MOLN

About CURI CuriosityStream Inc.

CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: